Biotech LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities March 9, 2026
Biotech U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma March 8, 2026
Biotech Aisa Pharma Announces Encouraging Results from Phase 2 RECONNOITER Trial of AISA-021 (Cilnidipine) in Patients with Systemic Sclerosis-Associated Raynaud’s Phenomenon March 7, 2026
Biotech Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line March 6, 2026
Biotech Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight March 5, 2026
Biotech ANANDA PHARMA LTD (“Ananda” or the “Company”) : MHRA and NHS Ethics Approval Received for ENDOCAN Phase 2 Clinical Trial for Endometriosis March 4, 2026
Biotech Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight March 3, 2026
Biotech Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma March 2, 2026
Biotech Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments March 1, 2026
Search
Biotech
March 10, 2026
March 9, 2026
March 8, 2026
March 7, 2026
March 6, 2026
March 5, 2026
March 4, 2026
March 3, 2026
March 2, 2026
March 1, 2026
